Cadence Pharmaceuticals, Inc. (CADX) Tops Q2 EPS by 8c, Revenue Falls Inline

Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) reported Q2 EPS of ($0.30), $0.08 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.62 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Espey Manufacturing (ESP) Tops Q4 EPS by 24c
• Scholastic Corp (SCHL) Misses Q1 EPS by 23c